Litigation Details for Bristol-Myers Squibb Company v. Apotex Inc. (D. Del. 2024)

Bristol-Myers Squibb Company v. Apotex Inc. (D. Del. 2024)

Docket	1:24-cv-00818	Date Filed	2024-07-15
Court	District Court, D. Delaware	Date Terminated	2025-11-12
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To
Patents	10,239,846; 11,680,050; 8,481,573; 8,796,318; 9,382,217
Link to Docket	External link to docket

Details for Bristol-Myers Squibb Company v. Apotex Inc. (D. Del. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-07-15				External link to document

Litigation summary and analysis for: Bristol-Myers Squibb Company v. Apotex Inc. (D. Del. 2024)

Last updated: July 22, 2026

Bristol-Myers Squibb v. Apotex Inc. (1:24-cv-00818) Litigation Summary and Patent-Value Analysis

Bristol-Myers Squibb Company (BMS) sued Apotex Inc. under 35 U.S.C. § 271(e) in case 1:24-cv-00818 filed in the US District Court (Docket number shown as “|1:24-cv-00818”). The dispute is a Paragraph IV-style patent infringement matter tied to Apotex’s FDA generic submission for a BMS-branded product. The case’s actionable details (asserted patents, drug, Orange Book reference product, filing date of the ANDA/§ 505(b)(2), and the status of any settlement) are not provided in the input, so a complete infringement, exclusivity, and “who wins and when” analysis cannot be produced from the supplied information.

What patents are asserted in Bristol-Myers Squibb v. Apotex 1:24-cv-00818?

A patent litigation summary depends on identifying, at minimum, the active ingredient, the FDA reference listed drug (RLD), the Orange Book patent numbers, and the exact asserted claims/patents listed in the complaint and any later amendments. Those fields are not included in the provided prompt.

Without the asserted-patent list, what can be concluded?

• No determination can be made on whether BMS asserts:
  • composition-of-matter patents,
  • formulation patents (e.g., specific salts, polymorphs, solid forms, or excipient systems),
  • method-of-use patents,
  • manufacturing/process patents, or
  • device/combination patents.
• No determination can be made on expected litigation posture (early summary judgment odds, claim construction targets, or design-around pathways) because those hinge on the asserted patent families.

Which BMS drug and Orange Book RLD are at issue in 1:24-cv-00818?

A credible litigation analysis must map the case to:

• the ANDA applicant (Apotex entity and submission details),
• the RLD (BMS product name),
• the Orange Book listing set (drug substance, drug product, and method-of-use patents), and
• the Paragraph IV notice date (and any later settlement triggering 30/75-day and forfeiture timelines).

None of these are present in the input.

What Orange Book status typically drives settlement strategy?

For Paragraph IV cases, parties’ leverage is driven by:

• the number of Orange Book patents listed for the RLD,
• whether any asserted patents expire early vs later,
• whether exclusivity is method-of-use vs formulation,
• whether the ANDA triggers pediatric exclusivity or 505(j) forfeiture complexities,
• whether the parties settle for “at-risk launch” protection or non-infringement licensing.

Those determinants cannot be applied without the RLD and asserted patent list.

When does Apotex’s potential generic entry risk begin for 1:24-cv-00818?

Generic entry timing is a function of:

1. Patent expiration dates for asserted patents (and any unasserted Orange Book patents that still block approval or trigger 30-month stay mechanics).
2. Regulatory exclusivities (NCE, pediatric, orphan, or other exclusivity codes for the RLD).
3. Injunction or settlement terms (timing carve-outs, launch dates, royalties, and “skinny labeling” arrangements).

The case record provided here contains only the docket identifier, not the underlying Orange Book or exclusivity facts needed to calculate:

• the earliest lawful approval date,
• the earliest lawful commercial launch date,
• or the “stay end” date (where applicable).

How strong is the patent estate in Bristol-Myers Squibb v. Apotex for this case?

Patent strength analysis requires:

• which patent families were asserted,
• their remaining term,
• whether they cover core product structure (composition/formulation) vs narrower method steps,
• prior art and prosecution history,
• whether similar estates have been invalidated or upheld in related litigations,
• and whether BMS previously enforced the same patents successfully.

No patent numbers, priority dates, filing/expiration, or litigation history are included in the prompt.

What an evidence-based strength score needs

• Asserted claim scope (independent claim elements).
• Apotex’s non-infringement or invalidity defenses.
• Court progress (Markman schedule, claim construction rulings, injunction motions).
• Any stipulations narrowing issues.

Those are not accessible from the provided input.

What does the litigation say about infringement theory (composition vs method of use) in 1:24-cv-00818?

Infringement theory drives:

• what the ANDA product must match (for composition/formulation patents),
• whether label carve-outs are required (method-of-use),
• and how “at-risk” launch could be designed to avoid the infringement hook.

Because the active ingredient, asserted claims, and asserted patent type are not provided, infringement theory cannot be characterized.

What defenses has Apotex raised in 1:24-cv-00818?

Standard § 271(e) generic defenses include:

• non-infringement,
• invalidity (35 U.S.C. §§ 102/103/112),
• unenforceability/inequitable conduct,
• failure to state a claim for specific asserted patents,
• and prosecution-history estoppel issues.

To summarize Apotex’s actual positions, the answer must cite the complaint, answer, invalidity contentions, or claim construction papers. None are in the prompt.

What litigation milestones and schedule are in the docket for 1:24-cv-00818?

A high-value litigation summary tracks:

• complaint filing date,
• service/response deadlines,
• scheduling order,
• Markman date and claim construction rulings,
• expert deadlines,
• summary judgment motions,
• trial dates (if any),
• and any injunction/supplemental orders. None of these dates are provided.

Has BMS and Apotex settled this case or entered a licensing agreement?

Settlement terms can include:

• “no-launch” commitments until a specific patent or date,
• covenants not to sue,
• license grants tied to specific patents or formulations,
• non-infringement positions in exchange for launch timing,
• and payments/royalty structures.

No settlement status or agreements are included in the prompt, so this section cannot be completed.

What is the likely commercial exposure for BMS if Apotex launches around this litigation?

Exposure depends on:

• the BMS product revenue at risk,
• the number of competitors,
• payer coverage dynamics,
• switching costs,
• and labeling/launch strategy.

No drug or commercial metrics are provided, so risk cannot be quantified.

How does this case compare with other BMS vs generic litigations (same asserted family patterns)?

Comparative analysis requires:

• the asserted patents,
• prior court outcomes,
• and the generic filing patterns (e.g., Apotex vs other challengers).

Without the patent family and RLD, comparison cannot be made.

Key Takeaways

• The input provides only the litigation docket identifier (1:24-cv-00818) and parties (BMS v. Apotex).
• A litigation summary and analysis that includes asserted patents, legal theories, procedural posture, and entry-timing implications cannot be completed without the case-specific facts (asserted patents, RLD/drug, Paragraph IV notice details, and docket milestones).

FAQs

1. What is a § 271(e) patent infringement case for an ANDA challenge?
2. How does Paragraph IV timing affect a generic launch date in US Hatch-Waxman litigation?
3. What are the typical differences in infringement proof for composition vs method-of-use patents?
4. How do settlements in Hatch-Waxman cases usually change launch timing and labeling?
5. What docket milestones determine how fast a patent case reaches trial or summary judgment?

References (APA)

1. Not available from the provided input.